Telix and ITM Join Forces to Create Radiopharma Powerhouse

Key points

• Telix to acquire ITM for $1.65 billion upfront
• Deal expected to close by end of FY 2026
• ITM shareholders to receive $1.25 billion in Telix shares
• Additional contingent consideration of up to $700 million based on regulatory approvals and sales milestones

Full summary

Telix Pharmaceuticals Limited (ASX: TLX) has announced a strategic merger with ITM Isotope Technologies Munich SE, a leading supplier of therapeutic radioisotopes. The merger aims to strengthen Telix's position as a vertically integrated radiopharmaceutical company, enhancing its capabilities in development, isotope production, and global manufacturing. ITM, a key supplier of lutetium-177 (177Lu), actinium-225 (225Ac), and terbium-161 (161Tb), will significantly contribute to Telix's supply chain and cash generation. The transaction, valued at $1.65 billion upfront, includes $1.25 billion in Telix shares and additional contingent consideration based on regulatory approvals and sales milestones for ITM-11, a novel therapeutic candidate for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The merger is expected to close by the end of FY 2026, subject to shareholder approval and regulatory conditions.

Guidance

Expected pro forma 2026 revenue and income exceeding $1.3 billion

Outlook

Combined organization expected to generate positive EBITDA contribution in 2027 and beyond, with potential for additional high-margin therapeutic revenue.